Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04060199 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)
A Phase 3 study, sponsored by NS Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 77
- Enrollment target
NCT04060199 is a Phase 3 study that has completed, run by NS Pharma. The registered enrollment target is 77 participants.
The verdict
NCT04060199, a Phase 3 study, has completed, sponsored by NS Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 77 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the efficacy of Viltolarsen compared to placebo in Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping.
Interventions
- DRUG Placebo
- DRUG Viltolarsen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2020-04-14 |
| Est. Completion | 2023-10-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04060199
The ClinicalTrials.gov registry entry for NCT04060199 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NS Pharma, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04060199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04060199 about?
NCT04060199 is a clinical study titled "Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)". The main objective of this study is to evaluate the efficacy of Viltolarsen compared to placebo in Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping.
What is the current status of trial NCT04060199?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 77 participants. The study started on 2020-04-14. Estimated completion is 2023-10-19.
What interventions are being tested in trial NCT04060199?
The interventions under investigation include: Placebo (DRUG), Viltolarsen (DRUG).
Who is sponsoring clinical trial NCT04060199?
This trial is sponsored by NS Pharma, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.